Oncology

News

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

News

Daiichi Sankyo has started clinical testing of a STING agonist for cancer, a class that has been hit by safety issues and discontinued programmes.

News

A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.

News

AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.

News

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

Oncology

Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.